MAIA Biotechnology Highlights Phase 2 THIO‑101 Expansion And Phase 3 THIO‑104 Trials Of Telomere Targeting Agent Ateganosine For NSCLC At SITC 2025; FDA Grants Fast Track Designation

Company confirms 12 patients enrolled in Phase 2 THIO-101 to date as expansion trial adds new countries

Posters for Phase 2 and Phase 3 clinical trials available

CHICAGO , Nov. 21, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced highlights from two poster presentations delivered at SITC 2025, an annual conference hosted by the Society for Immunotherapy of Cancer, held November 5-9, 2025, in National Harbor, MD. The Trials in Progress posters focus on MAIA's ongoing Phase 2 THIO-101 expansion (Part C) and Phase 3 THIO-104 clinical trials of its first-in-class small molecule telomere targeting agent, ateganosine, as a treatment for non-small cell lung cancer (NSCLC). The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for ateganosine for the treatment of NSCLC.